Novo Nordisk's CagriSema Outperforms Semaglutide in Phase 3 Diabetes Trial, But Faces Stiff Competition
New Phase 3 data for Novo Nordisk's CagriSema shows superior blood sugar control and weight loss compared to its own semaglutide in type 2 diabetes patients. However, analysts note the therapy enters a market where Eli Lilly's tirzepatide has already set a high bar for dual-benefit treatments.